Kite Pharma, Inc. (NASDAQ:KITE) Earns Average Broker Rating Of Outperform
Kite Pharma, Inc. (NASDAQ:KITE) stock is presently standing at about $85.92 and lots of equity research firms seem to have a target price set on the stock. The median one-year price target of 13 analysts covering the company is $85.00, which suggests the stock could still rise over -1 percent. The highest analyst price target is $95.00, which implies a rally of 89 percent. And a quick view of analyst notes show that 8 are rating the stock a buy while 6 rate KITE a strong buy. There are 2 equity research firms advocating a Hold and 0 consider it Sell.
Standpoint Research analysts provided their view on Kite Pharma, Inc. (NASDAQ:KITE) recently. The rating firm issued a Hold rating to this company in a research note released on Mar 13, 2017. Stifel analysts disclosed their opinion on Kite Pharma, Inc. (NASDAQ:KITE) recently. The rating firm gave a Hold rating to this stock in a research note published on Mar 03, 2017. According to a research note disclosed on Mar 02, 2017, analysts at Citigroup have lowered their rating on these shares from Buy to Neutral.
Kite Pharma, Inc. (NASDAQ:KITE) Transactions Roundup
Several insiders were part of recent insider activity for the stock. Its COO BUTITTA CYNTHIA M sold 21,118 company shares for 1705910, in a transaction on 2017-03-09. Following the transaction, the COO is left with a stake of 117,795 shares, currently valued at $10120946. Meanwhile, SVP Clinical Development Wiezorek Jeffrey sold 18,000 shares worth $1350180, through a transaction dated 2017-03-01. Following the completion of the transaction, the insider is left with a stake of 21,071 shares, amounting $1810420.32. KITE EVP, R&D, Chief Medical Off. Chang David D also sold 60,000 shares, at a stock price of $79.16. This transaction occurred on 2017-03-01 totals $4749600. After this transaction, the insider’s stake stands at 50,165 shares, with a market value of $4310177.
Executives hold 2.04 percent of the stock. Mr. Roy Doumani is one of the biggest insider owners in Kite Pharma, Inc. (NASDAQ:KITE), according to U.S. Securities and Exchange Commission (SEC) filings. The insider owns 131,017 shares which have current market value of around $11256980.64.Cynthia M. Butitta is another major inside shareholder in the company. The insider owns 117,795 shares as of 0.21%, currently worth $10120946.4. Steven B. Ruchefsky is ranked as third insider holder of the stock. This insider holds 87,988 shares with a market value around $7559928.96 as of recent close.
Kite Pharma, Inc. (NASDAQ:KITE) Earnings Outlook
In Kite Pharma, Inc. (NASDAQ:KITE)’s latest quarter, EPS moved to $-1.70 from $-1.49 in preceding quarter and revenues reached at $4.91M compared to $7.34M. Analysts had expected Kite Pharma, Inc. (NASDAQ:KITE) to post net income of about $-1.75 per share on $5.60M in revenue. Looking ahead, analysts on average predict that earnings for the current quarter would come in in the range of $-2.15 to $-0.88. That is compared with the $-0.90 in EPS it reported during the same period a year ago.